AASLD
Nov. 4–8, 2022

The Liver Meeting®

WASHINGTON D.C.

The Best of
The Liver Meeting®

LIVER AND BILIARY CANCER

About the program:

Best of The Liver Meeting 2022 was created by the Scientific Program Committee for the benefit of AASLD members, attendees of the annual conference, and other clinicians involved in the treatment of liver diseases. The program is intended to highlight some of the key oral and poster presentations from the meeting and to provide insights from the authors themselves regarding implications for patient care and ongoing research.

Use of these slides:

All content contained in this slide deck is the property of the American Association for the Study of Liver Diseases (AASLD), its content suppliers or its licensors as the case may be, and is protected by U.S. and international copyright, trademark, and other applicable laws. AASLD grants personal, limited, revocable, non-transferable and non-exclusive license to access and read content in this slide deck for personal, non-commercial and not-for-profit use only. The slide deck is made available for lawful, personal use only and not for commercial use. The unauthorized reproduction and/or distribution of this copyrighted work is not permitted.

Scientific Program Committee	
Chair	Laurie D. Deleve, MD, PhD, FAASLD
Co-Chair	Carla W. Brady, MD, MHS, FAASLD
President-Elect	Norah Terrault, MD, MPH, FAASLD
Senior Councilor	W. Ray Kim, MD, FAASLD
Annual Meeting Education Committee	Virginia C. Clark, MD, MS
Basic Research Committee	Bernd Schnabl, MD, FAASLD
Clinical Research Committee	Rohit Loomba, MD, FAASLD
CME Committee	Joseph K. Lim, MD, FAASLD
Hepatology Associates Committee	Elizabeth K. Goacher, PA-C, MHS, AF-AASLD
Inclusion and Diversity Committee	Lauren Nephew, MD, MAE, MSC, BA
Pediatric Hepatologist	Vicky Lee Ng, MD, FRCPC
Surgery and Liver Transplantation Committee	Bijan Eghtesad, MD, FAASLD
Training and Workforce Committee	Janice Jou, MD, MHS, FAASLD

AASLD
The Liver Meeting®

2

Cell-free DNA fragmentomes for detection of liver cancer

Objective

To develop a high-performing and cost-effective approach for cancer detection by examining genome-wide cfDNA fragmentation features, encompassed in fragmentomes.

Methods

We used a cross-validated machine learning model that incorporated genome-wide fragmentome features from blood samples of 391 individuals, including 47 individuals with HCC and 344 without cancer.

Main Findings

At 90% specificity, the overall sensitivity of the approach for detecting cancer was 94% among all individuals and 79% among high-risk individuals.

Conclusions

We demonstrate the use of genome-wide cfDNA fragmentome features to detect HCC with high sensitivity and specificity, including in early-stage disease (BCLC 0/A).

Machine learning model detects liver cancer with high sensitivity and specificity. Receiver operating characteristic (ROC) curves for the full cross-validated cohort and the fixed model applied to the validation cohort for full and high-risk cohorts.

Foda Z, et al., Abstract 201.

AASLD
The Liver Meeting®

3

Liver and Biliary Cancer

The Best of The Liver Meeting® 2022

AASLD   Nov. 4–8, 2022

The Liver Meeting®

WASHINGTON D.C.